3H Medi Solution and Genequest are collaborating to establish a patient registry for inflammatory bowel disease (IBD)
Initiating the provision of analysis information on differences in drug effects for each genetic polymorphism for contributing to the advancement of drug development and improvement in treatment options and treatment satisfaction for patients.
3H Medi Solution Inc. (Toshima-ku, Tokyo; CEO: Hirotaka Takizawa) and Genequest Inc. (Minato-ku, Tokyo; CEO: Osamu Iwata) have jointly conducted an analysis of a registry containing genetic and clinical information of patients with inflammatory bowel disease (IBD). This analysis provides insights into variations in drug effects and satisfaction levels based on genetic polymorphisms. The information derived from this analysis will contribute to the selection of new candidate compounds in drug development, streamlining patient recruitment in clinical trials, and expanding treatment options for patients. In the future, both companies plan to apply similar initiatives to a wide range of diseases, furthering their efforts to accelerate drug development and enhance patient treatment satisfaction.
◆ Overview of the IBD Patient Registry
Target Disease: Inflammatory Bowel Disease (Ulcerative Colitis and Crohn’s Disease)
Patient Population: 100 patients (80 with Ulcerative Colitis, 20 with Crohn’s Disease)
Collected Data: Genetic Information and Clinical Information (Treatment Progress, Medication
History, Lifestyle Information)
Analytical Data ：Pharmacogenomic Effects of Existing IBD Therapeutics by Gene Variants
Principal Investigators : Shun Nogawa (Genequest), Daisuke Maki (3H Life Science Research Institute)
◆ Details of the Provided Analytical Information
We explored the genetic variants related to the satisfaction levels concerning various medications taken by IBD patients. The results of this exploration suggest that there are genetic variants associated with different levels of satisfaction for each medication type. Part of the results is summarized in Table 1. For example, genetic variant B indicates a lower tendency for IBD development in individuals carrying this variant, while medication B is associated with higher satisfaction levels. Conversely, medication E is linked to lower satisfaction levels in individuals with this variant. This suggests that genetic variants may influence the suitability of medications. By utilizing these results, it is not only expected to assist in selecting medications tailored to individual patients but also to contribute to the development of more satisfactory medications. In addition to the results presented here, we will provide an analytical report that combines the obtained patient background information with newly acquired data.
◆ Effects of this Initiative
By participating in this ongoing survey, pharmaceutical companies gain access to continuous and regular information regarding the drug effects specific to the genetic variants of IBD patients. Additionally, understanding patient background information, treatment progress, and the Patient Journey (a record of the psychological changes that patients experience as they become aware of their illness, undergo treatment, receive support, and recover) can provide insights into new treatment interventions. It is also possible to conduct in-depth interviews with specific patients during this process. Furthermore, there are plans to incorporate quality of life (QOL) indicators into the ongoing survey, which is expected to enable the analysis of how drugs affect changes in QOL.
Patients, through this initiative, gain access to beneficial information regarding treatment for IBD patients, which becomes publicly available. Particularly, information about the effects of drugs based on genetic variants can be provided in a personalized environment, such as within the Genequest company’s members-only portal site. Moreover, patients who participate in this initiative have the opportunity to learn about the results of the research they contributed to by sharing some of the data analysis outcomes.
■Company Details
Company Name： 3H Medi Solution Inc.
Location： JRE Minami-Ikebukuro Building, 1-13-23 Minami-Ikebukuro, Toshima-ku, Tokyo 170-0014
Established： March 6, 2009
Capital： 20 million yen
CEO： Hiroki Takizawa, CEO
Business Activities: Subject Recruitment-Related Business, CRO-Related Business, Marketing-Related Business
URL： https://3h-ms.co.jp/
Company Name： Genequest Inc.
Location ： G-BASE Tamachi, 5-29-11 Shiba, Minato-ku, Tokyo 108-0014
Established： June 20, 2013
Capital: 1,100 million yen (including capital reserves)
CEO： Osamu Iwata, CEO
Business Activities: Personal Genetic Analysis Services
■Term Explanation
Genetic Polymorphism: Refers to variations in the base sequences of DNA’s adenine (A), thymine (T), guanine (G), and cytosine (C) that make up genetic information among individuals within a population or the polymorphisms (types) in that gene.
To know more please contact: imran@3h-ms.co.jp
